Delivery Order SPE2DB20D2104-SPE2DB23FR43A
- Not listed
- The federal contract award is for the delivery of Restasis 0.05% eye emulsion to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. This contract, valued at $4,965.76, is a delivery order issued under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. The IDC, valued at up to $999,999,999.00, serves as the...
- This federal contract award is for the delivery of Restasis 0.05% eye emulsion to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order with a firm fixed price of $3,326.76 and a completion date of January 26, 2022. The award was made on January 25, 2022, and there was no set-aside designation. Amerisourcebergen Drug Corp is a subsidiary of the parent...
- This federal contract award is for the delivery of Restasis 0.05% eye emulsion to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price type and a ceiling value of $3,339.00. It has an ultimate completion date of April 15, 2024. The contract is not designated with any set-aside requirements, indicating open competition....
- This federal contract award is for the delivery of Restasis 0.05% eye emulsion to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $1,350.60 and was awarded on February 1, 2022, with a completion date of February 2, 2022. This appears to be a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company,...
- This federal contract award is for the delivery of Restasis 0.05% eye emulsion to the Defense Logistics Agency (DLA), a component of the Department of Defense. The contract, valued at $3,325.95, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
- This federal contract award is for the delivery of Restasis 0.05% eye emulsion to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a firm fixed-price delivery order with a ceiling value of $8,729.62 and a completion date of October 20, 2021. The contract was awarded on October 19, 2021, and there was no set-aside designation. Amerisourcebergen Drug Corp is a subsidiary of...
- The federal contract award is for the delivery of Restasis 0.05% eye emulsion to support military and government healthcare programs. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,080.48, was awarded by the Defense Logistics Agency (DLA) as a firm fixed-price delivery order. It does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of...
- This federal contract award is for the delivery of Restasis 0.05% eye emulsion to the Defense Logistics Agency (DLA). The contract, valued at $15,912.49, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on February 5, 2023. This is a delivery order under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. The IDC serves as the primary vehicle for...
- This federal contract award is for the delivery of Restasis 0.05% eye emulsion to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is a delivery order with a ceiling value of $1,137.50, awarded on December 2, 2021, and with a completion date of December 3, 2021. The contract is for firm fixed-price and did not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a...
- This federal contract award is for the delivery of Restasis 0.05% eye emulsion to the Defense Logistics Agency (DLA) under a Firm Fixed Price Delivery Order. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor, which is a subsidiary of the parent company Cencora, Inc. The award has a ceiling value of $6,159.87 and a completion date of June 9, 2023. The contract is not designated with a set-aside requirement, indicating open competition. Amerisourcebergen...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB23FR43ADelivery Order
This federal contract award is for the delivery of Restasis 0.05% eye emulsion to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor that provides essential medical products to federal government agencies. The contract is a Delivery Order valued at $2,217.96 and has a completion date of December 14, 2022. It is not designated as a set-aside contract. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds significant Indefinite Delivery Contracts (IDCs) with the DLA Troop Support Medical, valued up to $999,999,999.00, and the Department of Justice Federal Bureau of Investigation, valued up to $750,000.00. These IDCs enable the efficient procurement of a comprehensive range of pharmaceutical products and medical supplies to support military, veterans, and other federal healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 12/13/22 |